Santersus Advances NucleoCapture® into Multinational Pivotal Study in Sepsis
Up to 350-patient randomized NUC-CAP study to assess safety, organ support and organ dysfunction in sepsis; Axcellant appointed global CRO to support execution ZURICH, SWITZERLAND, October 22, 2026 /EINPresswire.com/ — Santersus AG (“Santersus” or the “Company”), a privately held therapeutic medical device company advancing its NucleoCapture® selective blood purification platform, today announced the advancement of …
Santersus Advances NucleoCapture® into Multinational Pivotal Study in Sepsis Read More »